Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaKathryn G. Roberts, Timothy P. Hughes, Yongjin Li et al.|New England Journal of Medicine|2014Cited by 1.4k
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemiaZhaohui Gu, Williams E. Evans, Michelle L. Churchman et al.|Nature Genetics|2019Cited by 616
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaRobin Foà, Antonella Vitale, Marco Vignetti et al.|Blood|2011Cited by 460
The genomic landscape of pediatric acute lymphoblastic leukemiaSamuel W. Brady, Richard C. Harvey, Kathryn G. Roberts et al.|Nature Genetics|2022Cited by 394
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622William B. Slayton, Stephen P. Hunger, Kirk R. Schultz et al.|Journal of Clinical Oncology|2018Cited by 249